Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis
Brief Summary: This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.


Options:
A: Arm Label: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 50 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: PBO-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Arm Label: GLM-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 50 mg Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance, GLM-I-Rsp-Golimumab 50 mg Maintenance, GLM-I-nonRsp-Golimumab 100 mg Maintenance, Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, PBO-I-nonRsp-Golimumab 100 mg Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance
B: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Rectal tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rectal tacrolimus | Arm Label: Rectal Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rectal tacrolimus; Assigned to Arm(s): Rectal tacrolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Rectal Placebo
D: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D